Kinnate Biopharma Inc.
KNTE · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $13 | $25 | $26 | $27 |
| G&A Expenses | $6 | $7 | $8 | $8 |
| SG&A Expenses | $6 | $7 | $8 | $8 |
| Sales & Mktg Exp. | -$0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $2 | $0 | $0 |
| Operating Expenses | $19 | $33 | $34 | $35 |
| Operating Income | -$19 | -$33 | -$34 | -$35 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $2 | $2 |
| Pre-Tax Income | -$17 | -$31 | -$32 | -$33 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17 | -$31 | -$32 | -$31 |
| % Margin | – | – | – | – |
| EPS | -0.36 | -0.65 | -0.68 | -0.69 |
| % Growth | 44.6% | 4.4% | 1.4% | – |
| EPS Diluted | -0.36 | -0.65 | -0.68 | -0.69 |
| Weighted Avg Shares Out | 47 | 47 | 47 | 45 |
| Weighted Avg Shares Out Dil | 47 | 47 | 47 | 45 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$19 | -$33 | -$34 | -$34 |
| % Margin | – | – | – | – |